Definium Therapeutics (DFTX) director granted RSUs and 19,188 stock options
Rhea-AI Filing Summary
Definium Therapeutics director Suzanne Louise Bruhn received equity compensation on common shares. She was granted 4,666 restricted stock units, each representing one future common share, and a stock option for 19,188 common shares at an exercise price of $24.11 per share.
The RSUs and the stock option each vest as to 1/12 of the underlying shares on each monthly anniversary of the grant date, with remaining unvested awards vesting immediately before the company’s next annual meeting if it occurs within the first year, subject to her continued service. Following these grants, she directly holds 24,289 common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Bruhn Suzanne Louise
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 19,188 | $0.00 | -- |
| Grant/Award | Common Shares | 4,666 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 19,188 shares (Direct);
Common Shares — 24,289 shares (Direct)
Footnotes (1)
- These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one common share of the Issuer. The RSUs vest as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, any unvested RSUs will vest immediately prior to the Issuer's annual meeting following the date of grant, subject the Reporting Person's continued service through the applicable vesting date. The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares on each monthly anniversary of the date of the grant, provided, that if the Issuer's annual meeting immediately following the date of grant takes place prior to the first anniversary of the date of grant, the Stock Option will vest and become exercisable immediately prior to the Issuer's annual meeting following the date of grant, subject to the Reporting Person's continued service through the applicable vesting date.
Key Figures
RSU grant: 4,666 units
Stock option grant: 19,188 shares
Option exercise price: $24.11 per share
+4 more
7 metrics
RSU grant
4,666 units
Restricted stock units granted on June 11, 2026
Stock option grant
19,188 shares
Stock Option (Right to Buy) granted on June 11, 2026
Option exercise price
$24.11 per share
Conversion or exercise price for stock option
Option expiration
June 10, 2036
Expiration date for stock option
Shares after transaction
24,289 shares
Total common shares directly held following grants
RSU vesting schedule
1/12 monthly
RSUs vest monthly with potential acceleration before next annual meeting
Option vesting schedule
1/12 monthly
Stock options vest monthly with potential acceleration before next annual meeting
Key Terms
restricted stock units ("RSUs"), Stock Option (Right to Buy), contingent right, vests and becomes exercisable, +1 more
5 terms
restricted stock units ("RSUs") financial
"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (Right to Buy) financial
"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"
contingent right financial
"Each RSU represents a contingent right to receive one common share of the Issuer."
vests and becomes exercisable financial
"The Stock Option vests and becomes exercisable as to 1/12th of the underlying shares"
annual meeting financial
"immediately prior to the Issuer's annual meeting following the date of grant"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity awards did Definium Therapeutics (DFTX) director Suzanne Bruhn receive?
Suzanne Bruhn received 4,666 restricted stock units and a stock option for 19,188 common shares at an exercise price of $24.11 per share. These awards are part of her director compensation package and do not represent an open-market share purchase.
How do Suzanne Bruhn’s new RSUs at Definium Therapeutics (DFTX) vest?
The 4,666 restricted stock units vest in 12 equal monthly installments starting from the grant date. Any remaining unvested RSUs vest immediately before the next annual shareholder meeting if it occurs within one year, assuming she continues serving as a director.
What are the vesting terms of Suzanne Bruhn’s stock options at Definium Therapeutics (DFTX)?
The stock option for 19,188 common shares vests in 12 equal monthly installments from the grant date. If the next annual meeting occurs within one year, any unvested portion vests immediately before that meeting, contingent on her continued service with the company.
What is the exercise price and expiration date of Suzanne Bruhn’s Definium Therapeutics (DFTX) stock options?
Suzanne Bruhn’s stock options have an exercise price of $24.11 per share and expire on June 10, 2036. She may exercise vested portions any time before expiration, subject to plan terms and her continued service conditions.